News
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...
Alnylam Pharma raised its revenue outlook as its heart drug sees quick uptake.
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...
The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children ...
Moderna announced layoffs affecting 10% of its workforce amid government and competitive challenges to its vaccine business ...
The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval to those with at least one underlying condition that puts them at risk ...
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59 By Helen Branswell STAT,Updated June 13, 2025, 2:37 p.m.
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease Written by moderna inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results